Lenalidomidă Labormed

Lenalidomide, the active ingredient in Lenalidomidă Labormed, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle‑cell lymphoma in adult patients under the supervision of a qualified oncologist.

GNH USA supplies Lenalidomidă Labormed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Customers benefit from reliable logistics and transparent pricing.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple myeloma: reduces disease burden and prolongs survival in patients with relapsed or refractory disease. - Myelodysplastic syndromes: improves blood counts and decreases transfusion dependence in patients with del(5q) cytogenetic abnormality. - Mantle cell lymphoma: contributes to disease control in patients who have received prior therapies.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Nausea: feeling of sickness, sometimes with vomiting. - Rash: skin redness or itching. - Constipation: difficulty passing stools. - Peripheral neuropathy: tingling or numbness in extremities. - Low blood cell counts: anemia and thrombocytopenia. - Infections: increased susceptibility to bacterial or viral infections.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening.

When prescribing Lenalidomidă Labormed, clinicians should observe several safety precautions to minimize risk. - Pregnancy contraindication: avoid use in pregnancy; drug is teratogenic (Category X). - Thrombo‑prophylaxis: assess risk of clotting and consider anticoagulation in high‑risk patients. - Renal impairment: adjust monitoring and dosing in patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes and use caution in liver disease. - Infection monitoring: regularly evaluate for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Lenalidomidă Labormed can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding when combined with lenalidomide‑associated thrombocytopenia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide levels modestly. - Immunosuppressants (e.g., cyclosporine, tacrolimus): may enhance immunomodulatory effects and infection risk. - Vaccines: live attenuated vaccines should be avoided due to altered immune response.